Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Myeloma: early-phase trial registry
10 of 30 indexed Myeloma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #519 of 28,707 conditions by registered trial count.
30 US clinical trials · 10 currently recruiting · #519 of 28,707 conditions by registered trial count
Myeloma: 30 US clinical trials tracked, 10 recruiting.
Myeloma is the subject of 30 registered US clinical trials on ClinicalTrials.gov, 10 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 23 in Phase 1-2 (earlier-stage). The most active sponsor is David Rizzieri, MD, running 3 of these trials.
Enrollment posture brief
Registry condition myeloma
OPEN 10 | RECR 33% | LATE 0 | EARLY 23 | RANK #519 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Myeloma lists 10 open slots (33% of 30 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Myeloma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Myeloma is recruiting below its size-band peers.
10 of 30 indexed trials (33.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Myeloma trials is spread across many organizations.
David Rizzieri, MD accounts for 3 of 30 trials (10%). 19 distinct sponsors appear on at least one study for this condition label.
-
Most Myeloma trials plan to enrol fewer than 100 people.
Median target enrolment is 49 among the 30 trials that report a genuine target (sentinel values excluded). 24 of those (80%) plan for fewer than 100 participants.
-
Myeloma research is mostly interventional.
29 interventional and 1 observational studies make up this index (96.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
30 total, page 1 of 1
HEME Home Transfusion Program
Dana-Farber Cancer Institute
NCT06487247
Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
University of Miami
NCT05745285
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
K36 Therapeutics
NCT05651932
A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
Memorial Sloan Kettering Cancer Center
NCT07052916
Pilot Imaging Study of Leukemia
University of Oklahoma
NCT03633955
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
Omar Nadeem, MD
NCT06518551
Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma
M.D. Anderson Cancer Center
NCT06066359
Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy
University of Utah
NCT07390071
Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma
H. Lee Moffitt Cancer Center and Research Institute
NCT06947083
A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma
M.D. Anderson Cancer Center
NCT05055063
Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy
University of Arkansas
NCT00871013
Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma
University of Chicago
NCT03500445
PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study
Memorial Sloan Kettering Cancer Center
NCT01269593
Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL
Baylor College of Medicine
NCT00881920
Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma
University of Pennsylvania
NCT04680468
Ixazomib with Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients with Multiple Myeloma
Joseph Tuscano
NCT02542657
Exercise Prehabilitation Among Older Patients With Hematological Malignancies Preparing For CAR-T Cell Immunotherapy
H. Lee Moffitt Cancer Center and Research Institute
NCT05763563
Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant
David Rizzieri, MD
NCT00597714
Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath
David Rizzieri, MD
NCT00580034
Effects of Hyperbaric Oxygen (HBO) on Blood Count Recovery After Autologous Hematopoietic Stem Cell (HSPC) Transplant for Multiple Myeloma
Omar Aljitawi
NCT03398200
African American Cancer Clinical Trial Decisions: Testing Tailored Messages
Virginia Commonwealth University
NCT02356549
Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients
M.D. Anderson Cancer Center
NCT00469209
Allo Non-myeloablative SCT Utilizing Matched Family Member Stem Cells Purged Using Campath
David Rizzieri, MD
NCT00578942
Registry Study of T Cell Depleted Allo Non-Myeloablative Stem Cell Transplant
Duke University
NCT01904175
Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants
Duke University
NCT00606437
Stem Cell Transplantation for Patients With Multiple Myeloma
University of Chicago
NCT01526096
Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT01861340
Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy
H. Lee Moffitt Cancer Center and Research Institute
NCT05065866
PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative
Memorial Sloan Kettering Cancer Center
NCT01916135
Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy
Dana-Farber Cancer Institute
NCT00005988
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 15 |
| Phase 2 | 8 |
Top Sponsors
Named interventions
Most-linked intervention names on Myeloma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Myeloma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Myeloma page
30 registered trials, 10 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 10 Myeloma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- David Rizzieri, MD sponsors the most Myeloma trials on record, review their full trial history before evaluating a specific study. See David Rizzieri, MD's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Myeloma condition card totals 30 registered trials; most-linked intervention Dexamethasone; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.